Drugs / XS-03
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06936527 | May 2025 → Apr 2028 expected | colorectal cancer | NovaOnco Therapeutics Co., Ltd. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06936527 ↗ |
| Route | Oral | “XS-03 orally” NCT06936527 ↗ |